Pfizer Announces Positive Top-Line Data for Full Season Two

ABRYSVO, a bivalent vaccine, maintained consistently high protective efficacy for both RSV A and RSV B disease through two seasons after a single dose.



ABRYSVO efficacy was 77.8% against RSV...

Related Keywords

United States , Japan , Argentina , Macau , Canada , Alimentosy Tecnolog , Annaliesa Anderson , Pfizer , Administration Bureau Of Macau , Vaccine Research , Health Canada , Regulatory Agency , Youtube , Ministry Of Health , Centers For Disease , Forum Infect Dis , Pfizer Inc , Exchange Commission , Surveillance Research , Linkedin , Work Group Considerations , European Medicines Agency , Southern Hemispheres , Senior Vice President , Chief Scientific Officer , Nacional De Medicamentos , United Kingdom , Pharmaceutical Administration Bureau , Breakthroughs That Change Patient , Pfizer News , Annual Report , Looking Information , Factors That May Affect Future , Older Adults , New England Journal , Disease Control , Respiratory Syncytial Virus Infection , Updated December , High Risk , Respiratory Syncytial Virus , Human Metapneumovirus , Influenza Virus , Medically Attended , Systematic Review , Open Forum Infect , Respiratory Hospitalizations Attributable , Mortality Attributable , Influenza Type , Associated With Influenza , Teleconference Presentation ,